Aligos therapeutics doses first subject in phase 1 proof-of-concept study of small molecule drug candidate alg-000184 for chronic hepatitis b

South san francisco, calif., oct. 30, 2020 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has dosed its first subject in a first-in-human phase 1a/b clinical trial, alg-000184-201 (nct04536337). the study will evaluate alg-000184, a small molecule class ii capsid assembly modulator (cam) that targets hepatitis b virus (hbv) capsid assembly as well as the establishment of covalently closed circular dna (cccdna).
ALGS Ratings Summary
ALGS Quant Ranking